Blog

Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least

Photo of Rasika Bombatkar from gtc.ox.ac.uk

Feb 23, 2024, 14:31

Rasika Bombatkar: The rejection of my application for adjuvant Osimertinib is disheartening to say the least

Rasika Bombatkar, Citizen Scientist at LUNGevity Foundation, cancer patient and advocate, shared on X:

“AstraZeneca, your commitment to helping people access vital medicines is crucial and expected. However, the rejection of my application for adjuvant Osimertinib is disheartening to say the least.

Reply from your medical team states there is “no data on clinical benefits” with Osimertinib for someone like me with a stage III lung cancer with EGFR exon 19 deletion post surgery. Denying access to a proven lifesaver raises questions about the value placed on lives like mine.

Let’s ensure equitable access for all patients in need.”

Source: Rasika Bombatkar/X

access to treatment adjuvant EGFR inhibitor AstraZeneca cancer cancer patient EGFR exon 19 deletion Lung cancer OncoDaily Oncology osimertinib Rasika Bombatkar

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results